Evid Invest
Holders — by stockHoldings — by fund

General Catalyst Group Management, LLC

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 1637946

$188.5M

disclosed book value

14

positions

27.5%

largest position share

Positions, as of 2026-06-30

top 14 of 14 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1AVBPArriVent BioPharma, Inc.1.5M$51.9M27.5%
2PBLSParabilis Medicines, Inc.1.6M$43.8M23.2%
3CARTMaplebear, Inc.710,711$33.7M17.9%
4MAZEMaze Therapeutics, Inc.1.0M$30.9M16.4%
5ODTXOdyssey Therapeutics, Inc.810,272$15.2M8%
6EIKNEikon Therapeutics, Inc.305,233$4.0M2.1%
7GUTSFractyl Health, Inc.4.9M$3.9M2.1%
8LIFEEthos Technologies, Inc.74,179$1.3M0.7%
9CPNGCoupang Inc.54,677$949,7390.5%
10AMZNAmazon.com Inc.3,882$925,2360.5%
11METAMeta Platforms Inc.1,320$743,5430.4%
12DASHDoordash Inc.2,850$525,9110.3%
13CVNACarvana Co6,465$425,5260.2%
14FIGFigma, Inc.14,845$268,5460.1%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.